2024 | BioSenic

BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment

Read more about BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment

BioSenic conclut un accord avec Phebra PTY Ltd. concernant le développement de la première formulation orale du trioxyde d’arsenic pour le traitement de la cGvHD

Read more about BioSenic conclut un accord avec Phebra PTY Ltd. concernant le développement de la première formulation orale du trioxyde d’arsenic pour le traitement de la cGvHD

Notifications de transparence reçues de la part de François Rieger

Read more about Notifications de transparence reçues de la part de François Rieger

Transparency notifications received from François Rieger

Read more about Transparency notifications received from François Rieger

BioSenic nomme le Dr Carole Nicco au poste de directrice des opérations en plus de directrice scientifique

Read more about BioSenic nomme le Dr Carole Nicco au poste de directrice des opérations en plus de directrice scientifique

BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer

Read more about BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer

BioSenic signe un nouvel accord de souscription pour un maximum de 1,2 M€ en obligations convertibles

Read more about BioSenic signe un nouvel accord de souscription pour un maximum de 1,2 M€ en obligations convertibles

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds

Read more about BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds

Subscribe to 2024